Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 ABT-110 subcutaneous safety and pharmacokinetics study in healthy volunteers and chronic low back pain subjects
NL-OMON36923Phase 1Withdrawn
- Sponsor
- Abbott Laboratories
- Start
- Aug 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of Hu-alphaD11 in chronic low back pain (CLBP) (2 arms), sponsored by Abbott Laboratories. Primary endpoint: Pharmacokinetics, safety and tolerability in healthy volunteers. Planned start Aug 2012; status: withdrawn.
02
Drugs
Hu-alphaD11
03
Conditions
chronic low back pain (CLBP)
Beyond the preview
Go deeper on NL-OMON36923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36923.